OBJECTIVE: To describe urodynamic abnormalities in HTLV-1 infected individuals presenting urinary symptoms and verify if these findings and quality of life (QOL) evaluation correlate with overall neurological impairment. MATERIALS AND METHODS: From January/2001 to May/2004, 324 HTLV-1 seropositive subjects were evaluated to determine the occurrence of urinary symptoms. Urodynamic testing was performed in those who complained of frequency, urgency, or incontinence. They went through a complete clinical, neurological, and urological examination to investigate symptoms and signs of myelopathy. Neurological disability was assessed by Expanded Disability Status Scale (EDSS). RESULTS: From the 324 patients evaluated, 78 underwent the urodynamic testing. Fifty-seven individuals were females (73.1%) and age ranged from 23 to 76 years (mean=48.7 years; SD +/- 11.6). Urodynamic testing was abnormal in 63 patients (80.8%). The major abnormality was detrusor overactivity (DO), observed in 33 individuals (33/63; 52.4%), followed by detrusor-external sphincter dyssynergia (DESD), diagnosed in 15 subjects (15/63; 25.4%). HAM/TSP patients had significantly more DESD than the HTLV-I carriers (p=0.005; OR=5.5; CI: 1.6 to 19.4). QOL was severely compromised in HAM/TSP patients. CONCLUSIONS: Prominent urodynamic abnormalities were identified in individuals genuinely considered as HTLV-I carriers, suggesting an early compromise of the urinary tract; whereas HAM/TSP patients presented urodynamic findings, which posed a potential risk to the upper urinary tract (dyssynergia). Urodynamic evaluation should be performed in all HTLV-I-infected individuals with voiding complaints.
OBJECTIVE: To describe urodynamic abnormalities in HTLV-1 infected individuals presenting urinary symptoms and verify if these findings and quality of life (QOL) evaluation correlate with overall neurological impairment. MATERIALS AND METHODS: From January/2001 to May/2004, 324 HTLV-1 seropositive subjects were evaluated to determine the occurrence of urinary symptoms. Urodynamic testing was performed in those who complained of frequency, urgency, or incontinence. They went through a complete clinical, neurological, and urological examination to investigate symptoms and signs of myelopathy. Neurological disability was assessed by Expanded Disability Status Scale (EDSS). RESULTS: From the 324 patients evaluated, 78 underwent the urodynamic testing. Fifty-seven individuals were females (73.1%) and age ranged from 23 to 76 years (mean=48.7 years; SD +/- 11.6). Urodynamic testing was abnormal in 63 patients (80.8%). The major abnormality was detrusor overactivity (DO), observed in 33 individuals (33/63; 52.4%), followed by detrusor-external sphincter dyssynergia (DESD), diagnosed in 15 subjects (15/63; 25.4%). HAM/TSPpatients had significantly more DESD than the HTLV-I carriers (p=0.005; OR=5.5; CI: 1.6 to 19.4). QOL was severely compromised in HAM/TSPpatients. CONCLUSIONS: Prominent urodynamic abnormalities were identified in individuals genuinely considered as HTLV-I carriers, suggesting an early compromise of the urinary tract; whereas HAM/TSPpatients presented urodynamic findings, which posed a potential risk to the upper urinary tract (dyssynergia). Urodynamic evaluation should be performed in all HTLV-I-infected individuals with voiding complaints.
Authors: Rosana C P Andrade; José A Neto; Luciana Andrade; Tatiane S Oliveira; Dislene N Santos; Cassius J V Oliveira; Márcio J Prado; Edgar M Carvalho Journal: Urology Date: 2015-12-24 Impact factor: 2.649
Authors: Paulo Oliveira; Néviton M Castro; André L Muniz; Davi Tanajura; Julio C Brandão; Aurélia F Porto; Edgar M Carvalho Journal: Urology Date: 2010-02-26 Impact factor: 2.649
Authors: Michael A Sundberg; Davi Costa; Gloria Orge; Néviton M Castro; André Muniz; Marshall J Glesby; Edgar M Carvalho Journal: J Clin Virol Date: 2012-01-10 Impact factor: 3.168
Authors: Shelene K W Poetker; Aurelia F Porto; Silvana P Giozza; Andre L Muniz; Marina F Caskey; Edgar M Carvalho; Marshall J Glesby Journal: J Clin Virol Date: 2011-03-08 Impact factor: 3.168
Authors: Davi Tanajura Costa; André Luiz Muniz Alves dos Santos; Néviton Matos de Castro; Isadora Cristina de Siqueira; Edgar Marcelino de Carvalho Filho; Marshall Jay Glesby Journal: Arq Neuropsiquiatr Date: 2012-04 Impact factor: 1.420
Authors: Daniel J Morgan; Marina F Caskey; Cristiane Abbehusen; Jamary Oliveira-Filho; Cesar Araujo; Aurelia F Porto; Silvane Braga Santos; Gloria O Orge; Maria Jose Joia; Andre L Muniz; Isadora Siqueira; Marshall J Glesby; Edgar Carvalho Journal: AIDS Res Hum Retroviruses Date: 2007-12 Impact factor: 2.205
Authors: Glória O Orge; Thais R Dellavechia; José Abraão Carneiro-Neto; Lucas Araújo-de-Freitas; Carla H C Daltro; Carlos T Santos; Lucas C Quarantini Journal: PLoS One Date: 2015-05-27 Impact factor: 3.240